Kornimate/medical-research-clean huggingface dataset:
etoricoxib prescribing patterns and adverse events of interest in primary care in the united kingdom (mk-0663-162 am1)

Conditions: Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis; Gout; Arthritis

Summary: this postmarketing study was conducted to describe prescribing patterns for etoricoxib (arcoxia®) in general practice and describe the incidence of selected adverse events recorded in the united kingdom (uk) medicines and health care products regulatory agency (mhra) general practice research database (gprd).


Eligibility criteria:
inclusion criteria: * all patients in the mhra's full feature gprd (ff-gprd) who have at least one electronic outpatient prescription record for etoricoxib issued by a general practitioner during the period (april 1, 2002 to december 31, 2015) at the date of query execution against the ff-gprd data warehouse. exclusion criteria: * not registered in a gprd-contributing practice that had continuously collected data deemed to be 'up-to-standard' for research purposes from 1 april 2002 through to 31 december 2015. * never registered as a permanent patient of a general practitioner in the practice * registration details were not acceptable (i.e. incomplete data or logically implausible dates) * not registered with a general practitioner for at least 365 days before the date that the patient's first etoricoxib prescription was recorded in the gprd

Keywords: etoricoxib arcoxia osteoarthritis rheumatoid arthritis ankylosing spondylitis gout arthritis
indirect effects of pneumococcal vaccine on nasopharyngeal carriage

Conditions: Pneumococcal Infections

Summary: the purpose of this study is to assess the indirect effects of a pneumococcal conjugate vaccine administered to infants on vaccinees' elder non-vaccinated siblings aged 3 to 7 years.

the purpose of this study is to assess the indirect effects of a pneumococcal conjugate vaccine administered to infants on vaccinees' elder non-vaccinated siblings aged 3 to 7 years. this study includes a cross-sectional sampling of nasopharyngeal and oropharyngeal swabs in 2011 and a register-based follow-up study for invasive disease, hospital-diagnosed pneumonia, tympanostomy tube surgery and outpatient antimicrobial treatment.

Eligibility criteria:
inclusion criteria: * age 3 to 7 years * younger sibling at least 12 months of age living in the same household participates in the finip or 053 trial (regardless of the vaccination schedule) * at least one parent with fluent finnish * informed consent from one parent exclusion criteria: * commercial pcv vaccination administered * study-related pcv vaccination administered (open or blind) * history of antimicrobial treatment within 4 weeks (the child can be enrolled later)

Keywords: children pneumococcal vaccines
myocarditis treatment trial

Conditions: Cardiovascular Diseases; Heart Diseases; Myocarditis

Summary: to determine whether immunosuppressive treatment improved cardiac function in patients with biopsy-proven myocarditis.

background: heart failure due to myocarditis can be a devastating illness. at the same time, immunosuppressive therapy is associated with considerable risks of untoward side effects. clinicians did not know whether, under what circumstances, or in what form, this hazardous treatment should be used in such critically ill patients. in addition, if immunosuppressive therapy was of benefit, then endomyocardial biopsy in patients suspected of having myocarditis was a justified procedure. the trial also provided information concerning the side effects of immuno-suppressive therapy in such patients. design narrative: patients were randomized into two treatment arms consisting of conventional therapy alone for congestive heart failure or combined with a twenty-four week regimen of immunosuppressive therapy. immunosuppressive therapy consisted of prednisone with either cyclosporine or azathioprine. the primary outcome measure was a change in the left ventricular ejection fraction at twenty-eight weeks. secondary endpoints included survival, failures of therapy, requirements for conventional therapy, assessments of symptoms, myocardial histology, and arrhythmias. the study completion date listed in this record was obtained from the query/view/report (qvr) system.

Eligibility criteria:
men and women, 18 years of age or older, with left ventricular failure and biopsy-documented myocarditis.
development and validation of an internet-based near and intermediate-vision reading test

Conditions: Presbyopia; Refractive Errors; Low Vision; Near Vision; Reading

Summary: primary objective of our study is to develop and validate an internet-based digital near and intermediate-vision reading test in the greek language.

present study aims to develop and validate a computer-based digital near-vision reading test (web democritus digital acuity reading test - wddart) based on the validated digital ddart. specifically, present study aims to develop a new online reading test (wddart) based on the corresponding digital ddart reading test for windows and to evaluate the level of agreement between the two reading tests, as well as test-retest reliability of the online wddart reading test. the first part of the study is the development of the online reading test, which will include the following new smart features: 1. automatic calculation of the reading time of each sentence (each logmar) 2. automatic calculation of the basic reading parameters - ra, mrs, cps, acc - immediately after the completion of the examination 3. adjustment of the font size according to the size of the computer screen used for the examination 4. real time calculation of the patient-screen distance through a face detection system the second part of this study is the clinical validation of the online wddart reading test. in this part, four reading parameters measured with the digital and the online version are compared. these parameters are the following: 1. reading acuity (ra) 2. maximum reading speed (mrs) 3. critical print size (cps) 4. accessibility index (acc) all the comparisons take place in two groups: a) a normal vision group (nvg), and b) a low vision group (lvg) in order to estimate the reading capacity in a population with a wide range of vision.

Eligibility criteria:
inclusion criteria: * adequate literacy of written greek language * age between 18 to 75 years exclusion criteria: * dyslexia * attention-deficiency * former diagnosis of mental and/or psychiatric diseases

Keywords: internet-based digital reading test smart features face detection reading acuity reading speed critical print size
the effect of mitomycin c on corneal haze and scarring after corneal crosslinking in keratoconus patients

Conditions: Keratoconus

Summary: corneal crosslinking (crosslinking, cxl) is a treatment offered for the stabilization of early corneal ectatic disorders such as keratoconus. although cxl is an excellent treatment option to stabilize early ectatic corneas, complications include corneal haze, sterile infiltrate, endothelial cell toxicity, treatment failure and stromal scarring. corneal haze is a common finding in almost all cxl patients and may decrease visual quality. the effect of 0.02% mitomycin c (mmc) for 2 minutes on corneal haze and scarring in refractive surgery is well established in the literature with many clinical studies confirming its effectiveness. although the pattern of corneal haze after cxl appears to be different from the haze pattern seen following refractive procedures, both processes are thought to be caused by an inflammatory response. the investigators postulate that mmc can reduce post-cxl haze and scars when using the optimal concentration and duration of exposure.


Eligibility criteria:
inclusion criteria: * patients from both genders with confirmed keratoconus with evidence of clinical and topographic progression. * patients with the diagnosis of other ectatic disorders such as post refractive surgery ectasia with evidence of clinical and topographic progression. exclusion criteria: * patients who are pregnant * patients who are breast-feeding * patients who have allergy to mmc * patients with other corneal conditions such as limbal stem cell deficiency (lscd) * patients with peripheral marginal keratitis * patients with history of corneal melting * patients with history of hsv/vzv keratitis * patients with history of hydrops
exercise and rehabilitation after traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the purpose of this study is to examine the effects of exercise on recovery after traumatic brain injury. investigators will determine if exercise enhances rehabilitation by increasing substances (proteins) that can facilitate recovery.

exercise-based therapies can promote recovery of function and are easily implemented in the clinical rehabilitation setting. this study will determine if exercise facilitates recovery by improving markers of neuroplasticity and decreasing neuroinflammatory responses. the investigators will also determine if variations in genes involved in neuroplasticity, memory and inflammation influence the responsiveness to exercise and rehabilitation. particular genetic polymorphisms involved in neuroplasticity and inflammatory responses will be evaluated. recovery will be determined by assessing cognitive function, life quality and balance.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of tbi (for r+aer and r groups). * fluency in english or spanish. * able to walk with or without a device. exclusion criteria: * orthopedic or cardiac conditions that prevent from exercising. * current diagnosis of neurological and/or psychiatric diseases. unable to be in the los angeles ca metropolitan area for the duration of the study
self-supporting care model in home environment for patients with stroke

Conditions: Stroke; Activities of Daily Living

Summary: the purpose of this study was to administer intervention based on self-supporting care model in home environment and to explore the effects of this intervention on stroke patients' activities of daily living, movement, cognition, nutritional status, and quality of life.

subjects were randomized to intervention group and control group. the experiment was designed as randomized cross-over control trial. the primary outcome included 8 measures: barthel index-based supplementary scales, canadian occupational performance measure, fugl-meyer assessment, balance computerized adaptive testing, mini mental state examination-2nd edition, mini nutritional assessment, stroke impact scale, and stroke self-efficacy questionnaire.

Eligibility criteria:
inclusion criteria: * age \> 20 years * diagnosis of stroke * the modified rankin scale : 2\~4 * keep sitting for half an hour by himself/herself * follow instructions * willing to sign the subject's consent exclusion criteria: * diagnosis of dementia * history of orthopedic diseases or peripheral nerve injury * readmission because of stroke

Keywords: stroke self-supporting care model home care services
clinical and radiographic evaluation of two matrix systems for restoration of class ii cavities in primary molars

Conditions: Tooth Decay; Tooth Restoration

Summary: this study aims to evaluate and compare the clinical and radiographical efficacy, operator ease, satisfaction and patient comfort in restoring class ii cavities in primary molars using fender mate system with t-band system.

restorations of posterior primary teeth can have a number of issues, including incorrect contact points and proximal overhangs. with the recognition of significance of restoring tooth's right contour and contact, and repair of all tooth surfaces, including proximal walls, different matrix systems were introduced,so this study aims to evaluate and compare the clinical and radiographical efficacy, operator ease, satisfaction and patient comfort in restoring class ii cavities in primary molars using fender mate system with t-band system.

Eligibility criteria:
inclusion criteria: 1. apparently healthy children free from any systemic diseases. 2. patients showing frankel's positive and definitely positive behavior. 3. parent willing to participate in the study and signed on informed consent. 4. each child has at least two carious primary molars (class ii) bilaterally, indicated for composite restoration with criteria as follow: - * no history of spontaneous pain or provoked pain. * fully erupted teeth. * fully erupted adjacent tooth. * caries involving two surfaces - proximal and occlusal * absence of clinical signs or symptoms suggesting a non-vital tooth such as sinus tract, soft tissue swelling, mobility or tenderness to percussion. * no pathological external or internal root resorption. exclusion criteria: 1. patients showing frankel's negative and definitely negative behavior. 2. children having primary molars with: * caries involving less than or more than two surfaces * extensively damaged teeth * missing adjacent tooth. * mobility. * spaced dentition.

Keywords: matrix systems class ii cavities primary molars
the relationship between disease severity and various lower extremity parameters in individuals with knee osteoarthritis

Conditions: Knee Osteoarthritis; Knee Injuries

Summary: this study perform to investigate the relationship between quadriceps femoris (qf) strength, qf thickness, femoral cartilage thickness, knee function, balance, kinesiophobia and gait of the patients with knee osteoarthritis.

osteoarthritis (oa) is one of the most common chronic degenerative diseases in the world, which progresses slowly, can cause pain, stiffness and dysfunction, and reduces the quality of life. oa is particularly common in weight-bearing joints such as the knee and the functional status of patients with oa is adversely affected various factors such as immobility due to pain, decrease in muscle strength and joint range of motion, etc. in relation to this, walking difficulty and decrease in walking speed, balance problems and an increase in the risk of falling are a picture that can be encountered in the later stages of the disease. the aim of this study is to investigate the relationship between qf strength, qf thickness, femoral cartilage thickness, knee function, balance, kinesiophobia and gait of the patients with knee oa.

Eligibility criteria:
inclusion criteria: * volunteer patients who applied to the physical therapy and rehabilitation department with knee pain exclusion criteria: * individuals who have received intra-articular therapy for gonarthrosis in the last 6 months, who have undergone arthroscopic surgery, and who have additional pathologies in their lower extremities * individuals with physical, mental and/or psychological disorders that may affect participation in the study

Keywords: muscle thikness cartilage thickness balance postural stability kinesiophobia gait degeneration function
a dose escalation and combination immunotherapy study to evaluate bms-986226 alone or in combination with nivolumab or ipilimumab in patients with advanced solid tumors

Conditions: Cancer; Tumors; Neoplasm; Malignancy

Summary: the purpose of this study is to investigate bms-986226 administered alone or in combination with nivolumab or ipilimumab.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * advanced solid tumors * histological or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease as defined by response evaluation criteria in solid tumors (recist) v1.1 or pcwg3 (prostate only). * at least 1 lesion accessible for biopsy in addition to the target lesion * participants must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen * eastern cooperative oncology group (ecog) performance status ≤2 exclusion criteria: * participants with active central nervous system (cns) metastases, untreated cns metastases, or with the cns as the only site of disease are excluded (controlled brain metastases will be allowed to enroll) * participants with carcinomatous meningitis * prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast * active, known, or suspected autoimmune disease * uncontrolled or significant cardiovascular disease * participants with known allergies to egg products, neomycin and tetanus toxoid. * prior adverse reaction to tetanus toxoid- containing vaccines. other protocol defined inclusion/exclusion criteria could apply
preoperative prevalence of ulnar neuropathy and changes in ulnar nerve latency during surgery

Conditions: Ulnar Neuropathy

Summary: this study is to investigate the incidence of undiagnosed ulnar neuropathy in patients undergoing surgery. the investigators hope to determine if patients with ulnar neuropathy have changes in nerve conduction latency during surgery.

after obtaining an informed consent, the participating subjects will be asked a few questions relating to ulnar nerve dysfunction. following this the investigators will do a focused physical exam looking for decrement of sensation in the distribution of the ulnar nerve and muscle strength of the hand muscles supplied by the ulnar nerve. after this the subjects will undergo an emg exam to measure the conduction velocity of the ulnar nerve. basically the nerve will be stimulated with a small current and the resultant muscle activity of the hand muscle will be picked up using an ekg like patch applied to the skin over the hand. if a subject is diagnosed to have ulnar neuropathy preoperatively the investigators would study the emg based nerve conduction during surgery at 30-60 minute intervals for the duration of surgery. for purposes of comparison the investigators would measure the ulnar nerve conduction during surgery in age and sex matched controls.

Eligibility criteria:
inclusion criteria: * 50 yrs of age or older * scheduled to undergo a surgical procedure at utmc with an anticipated length of 2hours or greater exclusion criteria: * less than 50yrs * not scheduled for a surgical procedure at utmc or scheduled for a surgical procedure with an anticipated length of less than 2hours
a study of c-car066 in subjects with r/r diffuse large b cell lymphoma who received cd19 car-t therapy

Conditions: Diffuse Large B Cell Lymphoma

Summary: this is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of c-car066 in treatment of r/r dlbcl who received cd19 car-t therapy.

this study plans to enroll 10 patients to assess the safety and efficacy of c-car066. subjects who meet the eligibility criteria will receive a single dose of c-car066 injection. the study will include the following sequential phases: screening, pre-treatment (cell product preparation, lymphodepleting chemotherapy), c-car066 infusion and follow-up visit.

Eligibility criteria:
inclusion criteria: 1. the patient volunteered to participate in the study, and signed the informed consent 2. age 18-75 years old, male or female 3. patients diagnosed with diffuse large b-cell lymphoma (dlbcl, de novo or transformed) histologically according to the 2016 who classification, at least one measurable lesion(ldi≥1.5 cm) 4. r/r dlbcl patients who received prior cd19 car-t therapy, and positive for cd20 5. at least 2 weeks from last treatment (radiation, chemotherapy, mab, etc) to apheresis 6. adequate organ and bone marrow fuction 7. no contraindications of apheresis 8. expected survival time \> 3 months 9. ecog scores 0 - 1 exclusion criteria: 1. have a history of allergy to cellular products 2. patients with cardiac insufficiency classified as class iii or iv according to the new york heart association (nyha) heart function classification standard 3. a history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease 4. patients with active cns involvement 5. patients with autoimmune disease, immunodeficiency, or other treatment requiring inhibitors 6. severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. however, prophylactic antibiotics, antiviral and antifungal treatments are allowed 7. live vaccination within 4 weeks before peripheral blood apheresis 8. hiv, hbv, hcv and tppa / rpr infections, and hbv carriers 9. have a history of alcoholism, drug addiction and mental illness 10. non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception 11. patients with severe fludarabine or cyclophosphamide hypersensitivity 12. the patient has a history of other primary cancers, except for the following: 1. non-melanoma such as skin basal cell carcinoma cured by resection 2. cured carcinoma in situ such as cervical, bladder or breast cancer 13. the investigators believe that there are other circumstances that are not suitable for the trial
escitalopram treatment of patients with agitated dementia

Conditions: Alzheimer's Disease; Psychomotor Agitation

Summary: the purpose of this study is to determine the safety and efficacy of escitalopram (lexapro) using 10 or 20 mg daily in patients with alzheimer's disease who are also experiencing agitation.

this study is designed for men and women over 60 who have an established diagnosis of mild to severe alzheimer's disease and who also present behaviors of agitation such as restlessness, physical aggression, yelling and socially inappropriate interactions. while nonpharmacologic interventions are preferable, many times they are not effective alone. each consented subject will be enrolled in a 12 week study with escitalopram, 10 or 20 mg per day. each subject will be evaluated using rating scales designed for symptoms of alzheimer's and agitated behavior. each subject will also undergo physical and neurological examinations, laboratory tests and monitoring of side effects of escitalopram.

Eligibility criteria:
inclusion criteria: * dementia of alzheimer's type with behavioral disturbance * mild to severe cognitive impairment * age over 60 * medically stable * agitation present both at screening and baseline * agitation not responsive to simple nonpharmacologic interventions and lasting at least 2 weeks prior to enrollment. * available health care proxy or other legal representative to give informed consent, and patient assent. * no planned change in environment for duration of study * at least one reliable caregiver exclusion criteria: * any intercurrent medical problem that could explain the agitation * history of major depression or bipolar preceding the onset of dementia * other major psychiatric illness preceding the onset of dementia or mental retardation * other dementias * history of alcohol abuse or dependence in the last 2 years * delirium (or history of delirium in the last 8 weeks) * treatment with other psychotropic drugs except those permitted in the protocol. patients already treated for agitation with psychotropic medication must be able to successfully discontinue it and tolerate a washout period of no less than 1 week. * treatment with non-psychotropic, centrally active drugs believed to contribute to patient's agitation. * severe psychiatric symptoms requiring psychiatric hospitalization or suicidal, homicidal potential. * history of intolerance to citalopram * noncompliance with oral medication or inability to take oral medication * modified hachinski score of 4 or greater

Keywords: agitation dementia alzheimer's disease